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INTRODUCTION  
A STUDY ON RETROPERITONEAL SOFT TISSUE SARCOMA
1. INTRODUCTION
        
     Soft tissue sarcomas are the most frequent sarcomas.   They are a rare and 
heterogeneous group of tumors that arise from the supporting extra skeletal tissues 
(i.e.,  muscle,  fascia,  nerve,  connective,  fibrous,  and fatty tissues.  Although soft 
tissues comprise 75% of the average body weight, these neoplasms represent less 
than 1% of all adult and 15% of pediatric malignancies. Soft tissue sarcomas are a 
disease of  adulthood, occurring most  commonly in persons between 30 and 60 
years of age. The sole exception is rhabdomyosarcoma, which occurs in young 
children.
        Each of the various soft tissue sarcomas has a unique morphology, biological 
behavior,  and  prognosis.  However,  like  bone  sarcomas,  they  all  share  certain 
biological and behavioral characteristics. The clinical, radiographic, and surgical 
management of most soft tissue sarcomas is identical, regardless of histogenesis.
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      The treatment of soft tissue sarcoma has become multidisciplinary, as advances 
in biology, imaging, surgery, chemotherapy and radiotherapy have improved the 
outlook for these patients who have these malignancies. 
                 Fifteen percent of adult soft tissue sarcomas occur in the 
retroperitoneum. Most retroperitoneal tumors are malignant,  and about one-third 
are  soft  tissue  sarcomas.  The  most  common  sarcomas  occurring  in  the 
retroperitoneum  are  liposarcomas,  malignant  fibrous  histiocytomas,  and 
leiomyosarcomas.  In contrast to extremity sarcomas, local recurrence and intra-
abdominal spread are frequent patterns of relapse for retroperitoneal tumors.
The size at presentation depends on the location.
Tumors in the proximal extremities and retroperitoneum are often quite
large, whereas distal extremity tumors are often small. The anatomic
site of the primary disease represents an important variable that
influences treatment and outcome. Soft tissue sarcomas of the
extremities account for about 50% of all sarcomas, gastrointestinal (GI)
sarcomas for 25%, retroperitoneal sarcomas for 15-20%, and head and
neck for 9%. The most common subtypes of soft tissue sarcomas are
malignant fibrous histiocytoma, liposarcoma, leiomyosarcoma,
unclassified sarcoma, synovial sarcoma, and malignant peripheral
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nerve sheath tumors; however, more than 50 different histologic
subtypes of soft tissue sarcoma have been identified. Soft tissue
sarcomas most commonly metastasize to the lungs; tumors arising in
the abdominal cavity more commonly metastasize to the liver and
peritoneum.
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2. AIM OF STUDY
 
1. To study the incidence of retroperitoneal sarcoma in our institution.
2. To study age distribution and sex incidence.
3. To study stage of the disease at presentation.
4. To study the incidence of various pathological types.
5. To study the completion of resection of tumour and adjacent organs removed.
6. To study the incidence of the grade of the tumour.
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3. REVIEW OF LITERATURE
Embryogenesis of Retroperitoneum
Normal Development
     The  peritoneum  develops  around  the  third  week  of  embryonic  life. 
Differentiation to mesothelial cells by the primitive mesodermal lining of the early 
fetal coelomic cavity produces the parietal and visceral layers.
                The development of the retroperitoneal fasciae is enigmatic and obscure.  
The dorsal myotomes are responsible for the development of the psoas major and 
the quadratus lumborum muscles. The ventral myotomes are responsible for the 
genesis  of  the  transversus  abdominis  muscle.  Perhaps  both  myotomes  are 
responsible for the genesis of these periparietic fasciae, which are united at the 
lateral border of the psoas major muscle.
               The transversalis  fascia  and other  fasciae  related to  the lumbar 
musculature are of mesodermal origin. The muscles of the trunk are derived from 
dorsal  myotomes  of  truncal  somites  and  characteristically  maintain  their 
innervation from the  segmental  spinal  nerves at  the levels  of  the origin of  the 
muscles.
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Surgical Anatomy
                           The retroperitoneal space is the area of the posterior abdominal  
wall  that  is  located  between  the  parietal  peritoneum  and  the  deep  or  internal 
surface of the transversalis fascia. Within this space are embryologically related 
organs  which  are  referred  to  as  the  retroperitoneal  viscera.  These  include  the 
adrenals,  kidneys,  and  ureters.  There  are  also  numerous  vascular  and  neural 
structures,  including  the  aorta  and  its  branches,  the  inferior  vena  cava  and  its 
tributaries,  the  lymphatics  and  the  lymph  nodes,  the  lumbar  plexus  with  its 
branches, and the sympathetic trunks.
                          In addition to the organs and tissues that develop in the  
retroperitoneum, several other organs attain a secondarily retroperitoneal position 
in  later  embryologic  development.  These  include  most  of  the  duodenum,  the 
pancreas, and major portions of the ascending and descending colon.
                                       Within the greater retroperitoneal space, there are also  
several  small  spaces,  or  subcompartments.  Loose  connective  tissue  and  fat 
surround  the  anatomic  entities,  and,  to  a  variable  degree,  occupy  the  smaller 
spaces. The parietal peritoneum is in continuity with the visceral peritoneum, and 
vice versa.   
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 Fig
ure 
showing the important structures in retroperitoneum
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Compartments of the Retroperitoneal Space
Three compartments of the retroperitoneal space are related to the kidney: 
 
1.Anterior pararenal compartment 
2.Posterior pararenal compartment
3.Perirenal compartment
The renal fascia, a collagenous connective tissue of mesodermal origin enveloping 
the kidney, is responsible for this compartmentalization. 
The fascial layers and the spaces related to the kidney are as follows, from anterior 
to posterior: 
 • Peritoneum
• Anterior pararenal space (with a variable quantity of loose connective tissue 
and fat)
• Anterior lamina of Gerota's fascia
• Perirenal  space  (the  kidney  and  the  ureter;  the  adrenal  in  a  separate 
subcompartment; fat)
• Posterior lamina of Gerota's fascia
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• Posterior pararenal space (usually with a large content of more compact fat)
• Thoracolumbar (lumbodorsal) fascia and the fascia of the psoas muscle
                         To generalize, the muscle fascia lining the abdomen is referred to  
as  the  transversalis  fascia.  More  specifically,  however,  the  transversalis  fascia, 
which is the fascial lining of the transversus abdominis muscle, is continuous with 
the subdiaphragmatic fascia above. Medially, it is continuous with the psoas fascia 
and the thoracolumbar (or lumbodorsal) fascial investment (anterior lamina) of the 
quadratus lumborum muscle. Below, it is continuous with the fascia of the iliacus 
muscle and the parietal muscular fascia of the true pelvis.
Retroperitoneal Lymphatics
                      From an anatomic standpoint, the retroperitoneal lymph nodes can be 
rather  difficult  to classify.  The retroperitoneal  lymphatics  form a very rich and 
extensive chain from the inguinal ligament and pelvis to the respiratory diaphragm 
and posterior mediastinal nodes. Usually, these lymph nodes are located close to 
the aorta and IVC. The right paraaortic lymph nodes are in very close relationship 
with the left paracaval lymph nodes. The number of abdominal and pelvic lymph 
nodes is approximately 230.
The following classification is very simple, logical, and anatomic:
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 • Aortic Group 
  – Preaortic nodes
 –  Retroaortic 
nodes
 – Paraaortic nodes
• Caval Group
 
 
  – Precaval (prevenous) nodes
  – Retrocaval (retrovenous) nodes
  – Paracaval (laterovenous) nodes
• Pelvic Group
   – Common iliac nodes
  – External iliac nodes
  –  Internal iliac (hypogastric) nodes
  – Obturator nodes
  – Sacral nodes
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Retroperitoneal Innervation
                              Six nerves  and the lumbar sympathetic chains are present in  
the retroperitoneal space. The six nerves are branches of the lumbar plexus, which 
is formed by a branch of T12 as well as by the anterior primary rami of the first 
four lumbar nerves. Most of the branches of the plexus are related to the psoas 
major muscle, passing through it or behind it or being formed within it.
The nerves formed by the plexus are:
 • Iliohypogastric
• Ilioinguinal
• Genitofemoral
• Lateral femoral cutaneous
• Obturator
• Femoral
                            The retroperitoneum can be approached and explored by several  
routes, including the transperitoneal route and the extraperitoneal route. There are 
two accepted procedures used for  diagnosis  of  retroperitoneal  injuries  and for 
exploration of clinicopathological entities. The Cattell maneuver exposes right-
sided structures. The Mattox maneuver exposes left-sided structures.
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Cattell maneuver 
 
Step 1. Incise the lateral peritoneum along the cecum, ascending colon, and 
hepatic flexure
Step 2. Divide the white line of Toldt (peritoneal reflection at the area of the 
lateral wall of the cecum and ascending colon)
Step 3. Perform duodenal mobilization (Kocherization)
Step 4. Mobilize all right-sided anatomic entities anteromedially
Mattox maneuver 
 
Step 1. Incise the lateral peritoneum along the splenic flexure, descending 
colon, and upper sigmoid
Step 2. Divide the white line of Toldt
Step 3. Carefully mobilize the spleen, including the pancreatic tail, stomach, 
and left colon
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Step 4. Gently push all left-sided anatomic entities anteromedially
History
      The word sarcoma dates to Galen  and the Greek term describing a fleshy 
growth. The idea of a sarcoma as a distinct type of cancer was not formalized until 
the mid 1800s by Virchow.
Incidence
       Soft tissue sarcoma represents less than 1% of all adult and 15% of pediatric 
malignancies. Retroperitoneal sarcomas are rare tumors accounting for only 1%–
2% of all solid malignancies. Of all sarcomas, the majority occur outside of the 
retroperitoneum. Only 10%–20% of sarcomas are retroperitoneal sarcomas, and the 
overall incidence is 0.3%–0.4% per 100000 of the population . The peak incidence 
is in the 5th decade of life, although they can occur in any age group.
Distribution
     Soft tissue sarcoma can occur in any site throughout the body. Forty three 
percent are in extremities  with two thirds of extremity lesions occurring in the 
lower  limb,  and 34% are intra-abdominal,  divided between visceral  (19%) and 
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retroperitoneal (15%) lesions.  Trunk sarcoma occurs in 10% of individuals  and 
others in 10% of patients.
Etiology
        Most soft tissue sarcomas have no clearly defined cause, although multiple 
associated or predisposing factors have been identified.
        Various genetic syndrome  which are predisposing to soft tissue 
sarcoma  are  neurofibromatosis  type  1,  retinoblastoma,  LI-Fraumeni  syndrome, 
Gardner’s syndrome, Werner’s syndrome, Goblin’s syndrome, Carney’s triad and 
tuberous sclerosis.
       Radiation therapy is the known cause of soft tissue sarcoma. They are most  
often seen in diseases that are commonly treated with radiotherapy and in those in 
which a long survival period is expected. The prime candidate diseases are breast 
cancer, lymphoma, and cervical cancer. The children are at risk due to time latency 
involved. It arises close to penumbra of radiotherapy fields.
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Classification
 It is based on line of differentiation  i.e. the type of tissue formed rather than 
from the type of origin. WHO’s classification is used widely.
• Fibrous tumors
• Fibrohistiocytic tumors
• Lipomatous tumors
• Smooth muscle tumors
• Skeletal muscle tumors
• Tumors of Blood vessels & lymphatics
• Perivascular tumors
• Synovial tumors
• Mesothelial tumors
• Peripheral N. sheath tumors
• Primitive neuroectodermal tumors(PNET)
• Extra skeletal osseous & cartilagenous tumors
• Miscellaneous tumors
24
The basis cell appearance on smears, they are classified clinically as follows
• Myxoid tumors
• Spindle cell tumors
• Pleomorphic tumors
• Polygonal tumors
• Round cell tumors
• Miscellaneous
Pathology
The most common types of retroperitoneal soft tissue sarcomas in adults vary from 
study to study. However,  in most  studies,  the most  frequently encountered cell 
types  are  liposarcomas,  leiomyosarcomas  and  malignant  fibrous  histiocytomas 
(MFH) . Recently, the frequent diagnosis of MFH in the retroperitoneum has been-
disputed. With the use of immunohistochemistry, many of these fibrous tumors 
have now been shown to represent other sarcoma types such as leiomyosarcomas 
or dedifferentiated liposarcomas
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Retroperitoneal sarcomas generally present as large masses; nearly 50% are 
larger than 20 cm at the time of diagnosis. They typically do not produce 
symptoms until they grow large enough to compress or invade contiguous 
structures. The differential diagnosis of a retroperitoneal tumor includes 
lymphoma, germ-cell tumors, and undifferentiated carcinomas. The overall 
prognosis for patients with retroperitoneal tumors is worse than that for patients 
with extremity sarcomas.
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Fig 1 – showing retroperitoneal tumor presenting 
as abdominal mass (A) AP view ; (B) Lateral view
Fig 2 – Intra-operative picture of retroperitoneal 
sarcoma seen involving adjacent bowel loops
Grading of sarcoma
        After  establishing  the  diagnosis  of  sarcoma,  the  most  critical  piece  of 
information the pathologist can provide to the clinician is histologic grade. This 
remains  the  most  important  prognostic  factor  for  determining  disease-free  and 
overall survival rate.
        The pathologic features that define grade include cellularity, differentiation, 
pleomorphism, necrosis, and number of mitoses.
      Unfortunately, the criteria for grading are neither specific nor standardized. 
Several grading scales and systems are used:  a four-grade system (Broder’s),  a 
three-grade  system (low,  intermediate,  high)  such  as  National  Cancer  Institute 
(NCI)  grading  system  and  that  of  the  French  Federation  of  Cancer  Centers 
Sarcoma group, and a binary system (low, high) as is used at Memorial Hospital.
      Many pathologists consider mitotic activity and degree of necrosis to be the 
most  important  pathologic  features.  To  define  a  practical  grading  system,  the 
European Organization for Research and treatment of cancer (EORTC) conducted 
a study in which, the multivariate analysis showed only mitotic count (fewer than 
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Fig 4- showing a specimen of retroperitoneal liposarcoma
3, 3 to 20, and more than 20 mitoses per 10 consecutive high-power fields), the 
presence or absence of necrosis, and tumor size predicted survival.
Several tumors that are considered sarcomas have no recognizable normal 
tissue counterpart  (  e.g.,  alveolar soft  part tumor,  Ewing’s sarcoma,  Epithelioid 
sarcoma).  These tumors often have unique clinical  features and usually are not 
graded.  In  2002 AJCC/TNM staging system of  sarcoma,  only two grades,  low 
versus high are used to stage soft tissue sarcomas. To accurately determine tumor 
grade, an adequate tissue sample must be well fixed, well stained, and reviewed by 
an experienced sarcoma pathologist.
Staging
       Staging has an important role in determining the most effective treatment 
of  soft  tissue  sarcomas.  The stage is  determined  by the  size  of  the  tumor,  the 
histologic grade, and whether it has spread to lymph nodes or distant sites. For 
complete staging, a thorough physical examination, x-rays, laboratory studies, and 
careful review of all biopsy specimens (including those from the primary tumor, 
lymph nodes, or other suspicious lesions) are essential. CT chest done to find out 
lung metastases. CT abdomen and pelvis to find out the extension of tumour and 
liver metastases.
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               The staging system applies to all soft tissue sarcomas except Kaposi’s 
sarcoma,
dermatofibrosarcoma,  infantile  fibrosarcoma,  and  angiosarcoma.  In  addition, 
sarcomas arising within the confines of the dura mater, including the brain, and 
sarcomas  arising  in  parenchymatous  organs  and  from  hollow  viscera  are  not 
optimally staged by this system.
 
     Data to support this staging system are based on current analyses from multiple
institutions  and represent  the  recommendations  of  an  AJCC task  force  on soft 
tissue sarcoma.  In the era of cytoreductive neoadjuvant treatments,  clinical  and 
pathologic staging may be altered in the future. Because pathologic staging drives 
adjuvant therapy decisions, patients should be restaged after neoadjuvant therapies 
have been administered.
       Histologic type, grade, and tumor size and depth are essential for staging. 
Histologic grade of sarcoma is one of the most important parameters of the staging 
system. Grade is based on analysis of various pathologic features of a tumor, such 
as  histologic  subtype,  degree  of  differentiation,  mitotic  activity,  and  necrosis. 
Accurate grading requires an adequate sample of well-fixed tissue for evaluation. 
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Accurate  grading  is  not  always possible  on  the  basis  of  needle  biopsies  or  in 
tumors that have been previously irradiated or treated with chemotherapy.
Inclusions
       The present staging system applies to soft tissue sarcomas. Primary sarcomas 
can arise from a variety of soft tissues. These tissues include fibrous connective 
tissue, fat, smooth or striated muscle, vascular tissue, peripheral neural tissue, and 
visceral tissue.
Regional Lymph Nodes
      Involvement of regional lymph nodes by soft tissue sarcomas is uncommon in 
adults. When present, regional nodal disease has prognostic significance similar to 
that of visceral metastatic disease.
Metastatic Sites
      Metastatic sites for soft tissue sarcoma are often dependent on the original site 
of the primary lesion. For example, the most common site of metastatic disease for 
patients  with  extremity  sarcomas  is  the  lung,  whereas  retroperitoneal  and 
gastrointestinal sarcomas often have liver as the first site of metastasis.
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     TNM / The American Joint Committee on Cancer (AJCC)  has designated 
staging  by  the  four  criteria  of  tumor  size,  nodal  status,  grade,  and  metastasis 
(TNGM). 
Grade and TNM Definitions 
Tumor grade (G) 
• GX: Grade cannot be assessed 
• G1: Well differentiated 
• G2: Moderately differentiated 
• G3: Poorly differentiated 
• G4: Poorly differentiated or undifferentiated 
Primary tumor (T) 
• TX: Primary tumor cannot be assessed 
• T0: No evidence of primary tumor 
• T1: Tumor 5 cm or less in greatest dimension 
o T1a: Superficial tumor 
o T1b: Deep tumor 
• T2: Tumor 5 cm or larger in greatest dimension 
o T2a: Superficial tumor 
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o T2b: Deep tumor 
 Regional lymph nodes (N) 
• NX: Regional lymph nodes cannot be assessed 
• N0: No regional lymph node metastasis 
• N1: Regional lymph node metastasis  [Note: Presence of positive nodes (N1) 
is considered stage IV.] 
Distant metastasis (M) 
• MX: Distant metastasis cannot be assessed 
• M0: No distant metastasis 
• M1: Distant metastasis 
NOTES
1.  Superficial  tumor  is  located  exclusively  above the  superficial  fascia  without 
invasion
of  the  fascia;  deep  tumor  is  located  either  exclusively  beneath  the  superficial 
fascia,  superficial  to  the fascia  with invasion of  or  through the fascia,  or  both 
superficial  yet  beneath  the  fascia.  Retroperitoneal,  mediastinal,  and  pelvic 
sarcomas are classified as deep tumors.
2. Ewing’s sarcoma is classified as G4.
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STAGE GROUPING
IA      T1a       N0   NX   M0   G1–2     G1           Low
           T1b      N0   NX   M0   G1–2     G1           Low
IB       T2a      N0   NX   M0   G1–2     G1           Low
           T2b      N0   NX   M0   G1–2     G1           Low
IIA     T1a       N0   NX   M0   G3–4     G2–3       High
           T1b      N0   NX   M0   G3–4     G2–3       High
IIB      T2a      N0   NX   M0   G3–4     G2–3       High
III       T2b      N0   NX   M0   G3–4     G2–3       High
IV       Any T   N1           M0    Any G   Any G     High or Low
           Any T  Any N        M1   Any G   Any G    High or Low
Evaluation and Workup
The initial evaluation and workup for retroperitoneal abdominal soft
tissue sarcomas are similar to that for the extremity sarcomas. This
workup involves a thorough H&P and appropriate imaging studies,
including an abdominal and pelvic CT with contrast with or without an
MRI. Chest imaging with a plain radiograph or CT should be done,
especially for patients whose tumors warrant preoperative or
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postoperative chemotherapy. If possible, the patient should be
reviewed by a multidisciplinary sarcoma panel. Note that for staging, all
retroperitoneal  lesions  are  considered  to  be  deep  lesions.  MRI  is  preferred  for 
extremity sarcomas, whereas CT is preferred for retroperitoneal sarcomas.   
Radiologic  assessment  should  include  CT of  the  abdomen  and  pelvis  to 
define  the  extent  of  the  tumor  and  its  relationship  to  surrounding  structures, 
particularly vascular  structures.Imaging should also encompass the liver  for the 
presence of metastases, the abdomen for discontiguous disease, and the kidneys 
bilaterally for function. Thoracic CT is indicated to detect lung metastases.  For 
patients presenting with an equivocal history, an unusual appearance of the mass, 
an  unresectable  tumor,  or  distant  metastasis,  CT-guided  core-needle  or 
laparoscopic biopsy is appropriate to obtain a sample for tissue diagnosis
36
37
Fig 5 – Contrast enhanced CT Abdomen showing a huge retroperitoneal 
liposarcoma pushing the bowel loops to opposite side
18Fluorodeoxyglucose-positron  emission  tomography  (18FDG-PET)  scan 
may be useful for prognostication, grading and to assess response to chemotherapy. 
Tumor metabolism data acquired by FDG-PET will be useful in accurate grading 
and prognostication in sarcoma. Recent reports in literature have demonstrated the 
value of   FDG-PET scan in evaluating response to neoadjuvant chemotherapy in 
patients with high-grade extremity soft tissue sarcomas, prediction of outcome in 
liposarcoma.
BIOPSY
The differential diagnosis of retroperitoneal abdominal soft tissue mass
includes malignant lesions (such as other sarcomas, GIST, lymphomas,
or germ cell tumors), desmoids, and benign lesions. The need for a
biopsy remains somewhat controversial, and this decision should be
based on the clinician’s degree of suspicion that another malignancy is
possible. Proof of the histologic subtype by biopsy is necessary for
patients before receiving preoperative chemotherapy or RT; a
CT-guided core biopsy is preferred. The goal of this strategy is to avoid
inappropriate major resection of another tumor, such as an
intra-abdominal lymphoma or germ cell tumor. If a retroperitoneal
sarcoma is encountered unexpectedly at the time of laparotomy
performed for some other reason, a core biopsy should be done to
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establish the diagnosis as well as the histopathologic type and grade of
tumor. Then, the optimal subsequent resection could be performed.
Value of Trucut Biopsy
      In general, the important issue is the adequacy of the sample. Sufficient viable 
tissue  is  required  that  is  both  representative  of  the  lesion  and  available  for 
histopathologic evaluation, immunohistochemistry, and, when necessary, electron 
microscopy.  As  molecular  markers  become  a  factor  in  diagnosis,  meticulous 
attention to the adequacy of  biopsy,  tissue preservation,  and evaluation will  be 
paramount. 
      Histopathologic interpretation varies from center to center and may be a major 
variable in decision making. As with other relatively rare lesions, it is essential that 
review of the histopathologic findings be made by an experienced group. More 
recent studies show improved diagnostic accuracy and confluence of opinion, at 
least for malignancy and grade.
Fine-Needle Aspiration Cytology
        Fine-needle aspiration (FNA) cytology has been examined by a number of 
authors.  Some authors have argued that  biopsy itself  is  not  justified if  FNA is 
available.  But it is usually confined to the confirmation of recurrence rather than 
used for the primary diagnosis.
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     The  use  of  FNA in  patients  with  large  sarcomas  who are  candidates  for 
neoadjuvant therapy to improve survival is also problematic due to difficulty in 
grading and subtyping these tumors accurately from such small samples. 
Frozen Section
      In some institutions, frozen section is relied on as the diagnostic tool of choice. 
For diagnosis of malignancy, frozen section is accurate, but for  histopathologic 
subtypes  and  grade,  it  is  inferior  to  permanent  sections  of  either  Trucut  or 
incisional biopsy.
      Frozen  section  can  guide  retrieval  of  adequate  diagnostic  material  and, 
depending on the initial evaluation, can be an important triage mechanism to direct 
further  pathologic  workup.  However,  open  biopsy  with  the  help  of  frozen-
sectioning support may be indicated when the Trucut biopsy result is equivocal or 
for other clinical reasons. 
        Fatty lesions are not suitable for frozen-section evaluation, because of a loss 
of diagnostic material during frozen sectioning and other technical difficulties. In 
addition, freezing compromises the final interpretation on permanent sections.
      Important application of frozen section is assessment of margin of resection. 
Negative  margins  of  resection  can  be  obtained  by  using  this  technique 
intraoperatively.
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Immunohistochemistry
      As an ancillary technique, immunohistochemistry is an invaluable tool that 
provides excellent information in assisting the surgical pathologist in establishing a 
precise  diagnosis,  as  well  as  providing  relevant  prognostic  and  therapeutic 
information.
      One  of  its  major  utilities  is  to  correctly  identify  a  tumor  as  being  of 
mesenchymal  or  nonmesenchymal  origin.  Once  mesenchymal  origin  has  been 
established,  histologic  subtyping  according  to  specific  cell  lineage  may  be 
achieved with the use of lineage-specific markers. Tumors of uncertain cell lineage 
and tumors with primitive small round cell morphology are often characterized by 
a  unique  immunohistochemical  phenotype.  In  this  group  of  tumors, 
immunohistochemistry  is  most  widely  applied  and  is  of  greatest  value.  By 
diagnosing the small round cell tumors with aid of immunohistochemistry, line of 
management is differed from spindle cell soft tissue tumors.
       Despite  the  rapid  development  of  molecular  genetic  techniques, 
immunohistochemistry  still  remains  the  most  important  diagnostic  tool  in  the 
diagnosis of soft tissue tumors aside from recognition of morphologic features and 
clinical correlation.
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Primary Treatment
Surgery is the standard treatment for retroperitoneal abdominal
sarcomas. Complete surgical resection or macroscopic surgical
resection is only achieved in less than 70% of patients with primary
retroperitoneal sarcomas, because they often are near vital structures.
Local recurrence occurs in approximately half of the patients who have
undergone complete resection. Multimodality treatment is usually
favored for retroperitoneal sarcomas due to the inability to obtain
negative margin resections and high local recurrence rates.
Preoperative RT is often preferred, because the volume of abdominal
organs in the RT fields is smaller and it may render unresectable
tumors more amenable to resection. Preoperative chemotherapy may
have advantages over postoperative chemotherapy. However, the role
of adjuvant RT or preoperative chemotherapy vs. postoperative
chemotherapy has not yet been evaluated in randomized clinical trials.
         Primary treatment depends on the resectability of the sarcoma.  Biopsy is  
performed only if preoperative therapy is considered.  CT-guided core biopsy is 
preferred.
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Once the diagnosis is made, the surgical team needs to determine if 
the  retroperitoneal  sarcoma  can  be  resected.  Therefore  one  of  the  first 
determinations to be made is whether the tumor is localized, its local extent, and 
also if there is evidence of intra- or extra-abdominal metastatic spread of tumor. 
The location and size of the tumor, its relationship to adjacent organs, presence or 
absence of local extension, relationship to and/or involvement of major vascular 
structures, as well as the presence of normal anatomic variants and anomalies of 
major abdominal arteries and veins, are all crucial pieces of information that need 
to be provided. Since resection of one kidney is not uncommon, any radiographic 
evidence of unilateral renal dysfunction involving the kidney that is not adjacent to 
the tumor should be relayed to the surgical team. While it may be unavoidable that 
the patient will be left with a single poorly functioning kidney, the surgeon must be 
provided with all relevant information prior to attempted tumor resection.
Preoperative RT or preoperative chemotherapy (for chemo sensitive
histologies) could be considered. Although most patients with
retroperitoneal sarcomas (which are often liposarcomas) could be
managed with surgical resection with or without intraoperative RT
(IORT), the options for other therapy should be discussed, especially if
incomplete resection is a reasonable probability. Long-term results of
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two prospective trials showed favorable 5-year local recurrence-free
(60%), disease-free (46%) and overall survival rates (61%) among
patients who had R0 or R1 resection after preoperative RT for
intermediate or high grade retroperitoneal sarcoma.86 Postoperative RT
 could be considered in patients with pathologic findings
of high grade disease following negative margin resection or for
microscopic positive margins (R1 resection). Macroscopic positive
margins (R2 resection) should be managed as unresectable disease.
Unresectable retroperitoneal sarcomas are defined as tumors that
involve unresectable vital structures or tumors whose removal would
cause unacceptable morbidity. Biopsy is recommended before any
treatment for a patient with unresectable or metastatic retroperitoneal
sarcoma . Patients with unresectable or metastatic
disease have several options for primary treatment after biopsy
including chemotherapy or RT to downstage tumors prior to
resection. In asymptomatic patients, palliative surgery for symptom
control, best supportive care, or observation are additional options.
Unresectable tumors that become resectable following primary
chemotherapy or RT should be managed as described under
resectable disease.
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Following primary treatment, if patients have progressive disease or
remain unresectable with no downstaging of tumor, management
decisions depend on whether patients are symptomatic or
asymptomatic. Observation is considered for asymptomatic patients,
whereas for symptomatic patients, treatment options are similar to
those listed under primary treatment for unresectable or metastases.
Guidelines for Radiation Therapy
                    Sophisticated treatments with intensity-modulated radiation therapy
(IMRT) and proton-beam should be considered to improve therapeutic
effect.If resections with microscopically positive or grossly positive  margins are 
anticipated, surgical clips should be left in place to identify
high risk areas for recurrence, particularly for retroperitoneal or
intra-abdominal sarcomas . Total doses of RT should be
determined by normal tissue tolerance.
Preoperative RT
                   The usual dose of preoperative RT is 50 Gy. An intraoperative boost or
a postoperative boost with brachytherapy or an external-beam RT is
recommended for positive or close margins. Preoperative RT has
several advantages. First, the treatment volume is smaller, because the
need to cover the operative field is not present. Second, preoperative
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radiation may reduce seeding during surgical manipulation of the tumor.
The tumor may or may not regress with preoperative RT, but the
pseudocapsule may thicken and become acellular, easing resection
and decreasing the risk of recurrence. However, the main disadvantage
of preoperative RT is its effect on wound healing.A higher
complication rate has been observed when primary closure is used.
Therefore, involvement of a plastic surgeon in the team may be
necessary to reduce wound complications when preoperative radiation
is contemplated. After preoperative radiation, 3-6 weeks interval before
resection is necessary to decrease the risk of wound complications.
Very long intervals between resection and postoperative radiation are
not recommended.
If wide margins are obtained, additional radiation may not be needed.
Often, margins are close because of the proximity of many of these
tumors to major neurovascular bundles or bone. At the time of
resection, surgical clips should outline the area of recurrence risk.
Brachytherapy boosts should be delivered several days after surgery,
through catheters placed at operation, with doses of 12-20 Gy based on
margin status. Alternatively, a single intraoperative dose to the tumor
bed of 10-16 Gy, based on margin status, can be delivered immediately
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after resection with exposure of the area at risk, avoiding uninvolved
organs. External-beam RT boosts may be an alternative to
brachytherapy or intraoperative radiation: recommended doses are
10-14 Gy for close margins, 16-20 Gy for microscopically positive
margins, and 20-26 Gy for grossly positive margins. Many institutions
are no longer giving a boost after preoperative radiation to patients who
have widely negative margins, based on local control rates that
approach 95% with preoperative radiation at 50 Gy and negative
margins.
Postoperative RT
Postoperative RT has been to improve local control in patients with
high-grade extremity soft tissue sarcomas with positive surgical
margins.When surgical resection is the initial therapy, postoperative
RT choices include intraoperative radiation therapy (IORT),
brachytherapy or external beam RT. RT is not a substitute for
suboptimal surgical resection, and re-resection may be necessary. If
the patient has not previously received RT, one could attempt to control
microscopic residual disease with postoperative RT if re-resection is not
feasible.
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External-beam RT is delivered to large fields after surgical healing is
complete (at 3-8 weeks) to doses of 50 Gy. Most institutions include the
entire operative bed within that radiation field. Total doses of RT should
always be determined by normal tissue tolerance. For intraabdominal or
retroperitoneal tumors, this dose may be decreased to 45 Gy. An
intraoperative boost may not be possible if radiation morbidity is high.
If no intraoperative radiation or brachytherapy was used in the
immediate operative or postoperative period, an external-beam RT
boost should be added. For negative margins, an additional 10-16 Gy is
recommended to a reduced field that includes the original tumor bed,
based on grade and width of margins. For microscopically positive  margins,  an 
additional 16-20 Gy is recommended; for grossly positive
margins, an additional 20-26 Gy is suggested.
Brachytherapy alone has been used as an adjuvant in patients with
negative margins. 45-50 Gy to the tumor bed has been shown to
reduce recurrence without a significant effect on wound healing.
However, brachytherapy-alone techniques require special expertise
and significant experience. If brachytherapy is used as a boost, doses
of 10-20 Gy based on margin are recommended; a boost dose of 10-16
Gy for close margins or 20 Gy for positive margins is recommended.
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Recurrent Disease
              For patients with resectable, unresectable or disseminated recurrences,
the guidelines recommend the same management after biopsy, as
outlined for primary disease. Preoperative RT and/or
chemotherapy should be considered for recurrent disease, if not
administered previously. Palliative treatment for symptom control (RT,
chemotherapy or surgery) and best supportive care are potential
options that oncologists should discuss with symptomatic patients.
Enrollment in a clinical trial should be considered if an appropriate trial
is available.
Ewing's sarcoma and rhabdomyosarcoma are typically much more sensitive 
to  chemotherapy  than  are  other  adult  soft  tissue  sarcomas. Adjuvant  (or 
neoadjuvant) chemotherapy is the standard of care for adults with a diagnosis of 
rhabdomyosarcoma or Ewing's sarcoma. Typical regimens for small-cell pediatric 
sarcomas,  specifically  rhabdomyosarcoma  and  Ewing's  sarcoma,  include  the 
combination of vincristine, doxorubicin, and cyclophosphamide (dactinomycin, in 
particular,  for  rhabdomyosarcoma)  and  the  combination  of  ifosfamide  and 
etoposide.
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Surveillance
                    Patients with low-grade tumors that have been successfully resected
should have a follow-up physical examination with imaging
(chest/abdominal/pelvic CT) every 3-6 months for 2-3 years and then
annually. Patients with high-grade tumors that have been successfully
resected need more frequent surveillance. They should have a
follow-up physical examination with imaging (chest/abdominal/pelvic
CT) every 3-6 months for 2-3 years, then every 6 months for the next 2
years, and then annually. Chest imaging should be considered in both
cases.
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4. MATERIALS AND METHODS
              Patients admitted for retroperitoneal sarcoma between June 2004 to 
November 2008 in the Department of Surgical Oncology, Government Royapettah 
Hospital, Chennai were taken for study.
 
        Data were collected in all patients. Patient’s age and sex were noted. Histories 
like  abdominal  mass,  its  duration,  presence  of  pain  and  its  duration,  other 
symptoms and family history were recorded. Previous history of surgery, biopsy if 
any and treatment were taken. Physical examination was done to note site, size of 
swelling and presence or absence of metastases. Chest x-ray , CT abdomen and CT 
chest  were taken in all  patients.  Histopathology, grade,  and margin status were 
noted.  Histopathology  is  compared  with previous  reports.  Follow up was  done 
once in every 3-4 months in 1-2 year and once in 6 months in 3-5 yrs and then 
thereafter annually once. Follow up was done with CT abdomen and pelvis and 
chest x ray, CT chest if required. 
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5. OBSERVATION AND ANALYSIS
Retroperitoneal  sarcoma consisted  of  0.16% of  all  cancers  admitted  from June 
2004 to November  2008.  Retroperitoneal  sarcoma forms 10 – 20% of  the soft 
tissue sarcomas according to Mettlin, C.Prior et al , but in this study it accounts to 
9.85% of soft tissue sarcomas.
Cancers Number Percentage
Retroperitoneal sarcoma 21 0.16
Others 12990 99.83
Total 13011 100
Cancers Number Percentage
Retroperitoneal sarcoma 21 9.85
Other Soft tissue sarcoma 192 90.14
Total 213 100
In this study incidence of retroperitoneal sarcoma was seen more in males than in 
females in a ratio of males:females=2.5:1
Sex Frequency Percentage
Male 15 71.42
Female 6 28.57
Total 21 100
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                                     According to literature, the most common histopathologic  
types  in  the  retroperitoneum  are  liposarcoma  (40%),  leiomyosarcoma  (25%), 
MPNST, and fibrosarcoma.  Approximately 55% of retroperitoneal  liposarcomas 
are  well  differentiated  and low grade,  with tumors  in  roughly  40% of  patients 
showing dedifferentiated, high-grade histologic features at primary presentation.In 
this study , the results are the same as that of literature with liposarcoma (52.38%) 
being the most common histopathology.
Histopathology Frequency Percentage
Liposarcoma 11 52.38
Leiomyosarcoma 4 19
PNET 3 14.3
Rhabdomyosarcoma 1 4.7
MPNST 2 9.5
Total 21 100
                                                          As per literature, the peak incidence is in the  
5th decade of life, although they can occur in any age group. Study findings bides 
with literature results with peak incidence in 5th decade, accounting about 33.33% 
of the all age groups .
Age groups(yrs) Frequency Percentage
<20 2 9.5
21-30 4 19
31-40 1 4.7
41-50 7 33.33
51-60 3 14.3
61-70 3 14.3
>70 1 4.7
Total 21 100
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                            Most of the retroperitoneal sarcoma are large in size at the time 
of presentation and are considered as deep tumors according to the AJCC staging. 
All belong to T2b. In this study , the average size of the tumor at presentation is 
15.19 cm. The median size of retroperitoneal sarcoma is 25cm.
As per literature , most of the retroperitoneal sarcoma are seen in Stage III 
accounting to 62%. 
      
Stage Frequency Percentage
IA - -
IB 7 33.33
IIA - -
IIB - -
III 13 62
IV 1 4.7
Only one case was found to be in Stage IV in this study.
At the time of presentation, majority were primary tumors but few of them were 
recurrent .
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Presentation Frequency Percentage
Primary 19 90.47
Recurrence 2 9.52
Total 21 100
Out of the two recurrent cases , one of them was a case of second time recurrence 
and the other 3rd time recurrence. Management and work up plan of the recurrences 
were managed like as for primary tumors.
Most patients present with an asymptomatic abdominal mass. On 
occasion pain is present, and less common symptoms include gastrointestinal 
bleeding, incomplete obstruction, and neurologic symptoms related to 
retroperitoneal invasion or pressure on neurovascular structures. Weight loss is 
uncommon, and incidental diagnosis is the norm. In one report, neurologic 
symptoms related primarily to an expanding retroperitoneal mass were identified in 
27% of patients.
Symptoms Frequency Percentage
Abdominal pain 10 47.6
Abdominal mass 6 28.5
GI Bleed 1 4.7
Neurologic 9 42.85
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Some of the patients came with more than one complaint. Abdominal pain was the 
major complaint most of the patients in this study accounting about 47.6% . 
Neurologic symptoms was found to be high  42.85% when compared to the 
literature values 27%.
According to the literature it is difficult to give adequate clearance in 
case of retroperitoneal sarcoma because of adjacent vital structures. 
Frequency Percentage
Complete resection 8 35
Incomplete resection 1 4.7
Inoperable 6 28.5
Metastasis 1 4.7
Chemotherapy without 
surgery
5 23.8
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Majority of the cases were resectable , but less when compared to literature results. 
In this study only one case was incompletely resected and in literature incomplete 
resection is acceptable only in case of a retroperitoneal sarcoma with well 
differentiated liposarcoma as the histopathology. In such cases the long term 
survival is significantly increased , whereas in other cases incomplete resection has 
the same survival rates as those without surgery. 
Out of the 8 cases which had complete resection , 3 cases were 
positive for margins . These cases were subjected to post operative radiotherapy. 
Margin Frequency Percentage
Positive 3 37.5
Negative 5 62.5
Total 8 100
In a study of 28 patients with liposarcomas, adjacent organ 
resection was carried out in more than half the cases, with partial or total resection 
of the kidneys in 60%, colon in 50% and adrenal glands in 35% . Although 
nephrectomy was performed in 60% of cases, the kidney itself was rarely involved. 
Nevertheless, the encompassment of the kidney and the involvement of the hilar 
renal vasculature make the resection of the kidney often necessary.
Adjacent organs removed Frequency Percentage
Kidney 6 66.66
Bowel loops 5 55.55
Total 11 100
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In this study, 9 cases went in for adjacent organ resection. 
Nephrectomy was the most common procedure done along with resection of the 
tumor. Left kidney removal (55.55%) was more common than right kidney 
removal (11.11%). Most common bowel loops to be resected was descending 
colon. In most of the cases , descending colon was completely removed and distal 
2/3 rd  transverse colon was anastomosed to either sigmoid colon or rectum.
Majority of cases which are inoperable are due to vascular 
involvement(19%). Vascular structures commonly involved are inferior venacava 
and common iliac veins.
Blood Vessel Frequency Percentage
IVC 2 50
Common iliac vein 2 50
Total 4 100
             In this study no vascular resection and reconstruction was done. Such cases 
were given post operative radiotherapy but overall survival was the same. 
Radiotherapy helped in local control only in few patients and tumor was 
progressive in some cases.
               Out of the 21 cases , 12 cases (57.14%) had previous biopsy done. 
According to literature pre operative biopsy is only essential in case of soft tissue 
sarcoma of the extremity whereas not required in case of retroperitoneal sarcoma. 
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Pre operative biopsy is required in case of high suspicion  when there is chance of 
the retroperitoneal tumor being a lymphoma or primitive neuroectodermal tumor 
where such radical resection is not at all required as they are curable by 
chemotherapy alone.      
                                 The grading of the post resection tumor was compared with 
previous biopsy results and were the same. In this study high grade tumors 
accounted to 66.66%. 
Grade Frequency Percentage
High 14 66.66
Low 7 33.33
Total 21 100
                              According to literature most of the retroperitoneal sarcoma are 
low grade well differentiated tumors  unlike the reports of this study.
                          In this study 5 cases had adjuvant and neoadjuvant chemotherapy . 
Especially Primitive neuroectodermal tumour(PNET) , Malignant peripheral nerve sheath 
tumour (MPNST) and Rhabdomyosarcoma responded well to chemotherapy. 
Radiotherapy and chemotherapy was also tried in inoperable and marginally positive 
tumors. The outcome was poor to both therapies. The chemotherapy regimen commonly 
used in our institute was PVCE regimen consisting of  Cisplatin, Vincristine, 
Cyclophosphamide, Etoposide. The patients could not be followed up completely except for 
a few with CT chest and CT abdomen. 
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6. Conclusions
                            In this study, retroperitoneal sarcoma is a rare sarcoma 
accounting to 0.16% incidence of all cancers and forms 9.85% of all soft tissue 
sarcoma .Most of it occurs in males than in females in a ratio of 2.5:1. As with 
other series the age incidence is mainly in the 5th decade. 
                                 The major histopathology of the retroperitoneal sarcoma is  
liposarcoma followed by leiomyosarcoma.  Majority  of  the cases  at  the time of 
presentation were about 15cm in diameter and most belonged to Stage III. (62%)
                                             Abdominal pain, discomfort and neurologic pain were  
the most common presenting complaints. Majority were primary tumors and only 
9.52%  being  recurrent  tumors.35%  of  tumors  were  completely  resectable  and 
28.5% were inoperable  due to  involvement  or  proximity  to  vascular  structures. 
Only one case of metastasis was reported.
                62.5% of operated cases were margin negative. Most of the tumors were  
high  grade  tumors  (66.66%).  Most  of  the  resections  involved  adjacent  organ 
removal with bowel loops and kidney being the common adjacent organs removed. 
Kidney  (66.66%)removal  was  slightly  more  common  than  bowel  removal 
(55.55%). Vascular involvement was seen in 19% of the cases.
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                             Only primitive neuroectodermal tumor and rhabdomyosarcoma  
showed good results with chemotherapy. Radiotherapy had no significant role in 
controlling local spread as well as on survival benefits.
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PROFORMA
Name: Occupation: DOA:
Age/Sex: IP/CD No: DOS:
Phone No: DOD:
DIAGNOSIS:
Staging:
Complaints:  Abdominal pain – 
                       Abdominal mass – 
                                      GI Bleed – 
                                Obstruction – 
           Neurological symptoms – 
Previous H/O malignancy:
Previous H/O biopsy:
Comorbid illness:
Treatment H/o:
H/O Recurrences:
Family H/O Cancer:
Investigations:
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USG Abdomen – 
Chest X-ray – 
CT abdomen – 
CT chest – 
Biopsy -         histology =
                             Grade =
Immunohistochemistry=
Surgery:   Complete / incomplete resection:
                  Margin negative / not :
                Adjacent organs removed :
                Vascular resection :
Post-op complications:  
Post-op HPE:  
Radiotherapy:
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